# Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

> **NCT05994001** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 78 (actual)

## Conditions studied

- Biliary Tract Cancer
- Candonilimab
- Claudin 18.2

## Interventions

- **DRUG:** cardonilizumab
- **DRUG:** LM-302

## Key facts

- **NCT ID:** NCT05994001
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05994001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05994001, "Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05994001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*